{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:55:17Z","timestamp":1794099317383,"version":"4.8.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Key Research and Development program of Hunan Province","award":["2022SK2029"],"award-info":[{"award-number":["2022SK2029"]}]},{"name":"the National Natural Science Foundation of China Projects","award":["81800271"],"award-info":[{"award-number":["81800271"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-03892-8","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T14:35:51Z","timestamp":1738161351000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Initial treatment with a single capsule containing half-dose quadruple therapy vs standard-dose dual therapy in hypertensive patients (QUADUAL): a randomized, blinded, crossover trial"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2570-7390","authenticated-orcid":false,"given":"Xiexiong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0776-2900","authenticated-orcid":false,"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4240-3468","authenticated-orcid":false,"given":"Xiaohong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingle","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongshu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixiong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaogang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8369-9694","authenticated-orcid":false,"given":"Weihong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"issue":"6","key":"3892_CR1","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","volume":"38","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens. 2020;38(6):982\u20131004.","journal-title":"J Hypertens"},{"issue":"3","key":"3892_CR2","first-page":"182","volume":"16","author":"Joint Committee for Guideline, Revision","year":"2019","unstructured":"Joint Committee for Guideline, Revision. 2018 Chinese guidelines for prevention and treatment of hypertension-a report of the revision committee of Chinese guidelines for prevention and treatment of hypertension. J Geriatr Cardiol. 2019;16(3):182\u2013241.","journal-title":"J Geriatr Cardiol"},{"issue":"10258","key":"3892_CR3","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"G. B. D. Risk Factors Collaborators","year":"2020","unstructured":"G. B. D. Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1223\u201349.","journal-title":"Lancet"},{"issue":"6","key":"3892_CR4","first-page":"521","volume":"36","author":"The Writing Committee of the Report on Cardiovascular Health and Diseases in China","year":"2021","unstructured":"The Writing Committee of the Report on Cardiovascular Health and Diseases in China. Report on cardiovascular health and diseases burden in China: an Updated Summary of 2020. Chin Circul J. 2021;36(6):521\u201345.","journal-title":"Chin Circul J"},{"issue":"10112","key":"3892_CR5","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1016\/S0140-6736(17)32478-9","volume":"390","author":"J Lu","year":"2017","unstructured":"Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet. 2017;390(10112):2549\u201358.","journal-title":"Lancet."},{"issue":"19","key":"3892_CR6","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/j.jacc.2017.11.005","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):2199\u2013269.","journal-title":"J Am Coll Cardiol"},{"issue":"34","key":"3892_CR7","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"},{"issue":"6","key":"3892_CR8","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1097\/HJH.0000000000002072","volume":"37","author":"P Lopez-Jaramillo","year":"2019","unstructured":"Lopez-Jaramillo P, Barbosa E, Molina DI, Sanchez R, Diaz M, Camacho PA, et al. Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome. J Hypertens. 2019;37(6):1126\u201347.","journal-title":"J Hypertens"},{"issue":"9","key":"3892_CR9","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42(9):1235\u2013481.","journal-title":"Hypertens Res"},{"key":"3892_CR10","first-page":"247","volume-title":"Internal medicines","author":"G Junbo","year":"2018","unstructured":"Junbo G, Yongjian X, Chen W. Internal medicines. Beijing: People\u2019s Medical Publishing House; 2018. p. 247\u201350."},{"issue":"4","key":"3892_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2174\/15748847113086660075","volume":"10","author":"P Naik","year":"2015","unstructured":"Naik P, Gandhi H, Pawar V, Giridhar R, Yadav MR. Management of hypertension-journey from single drug therapy to multitargeted ligand therapy: a clinical overview. Curr Clin Pharmacol. 2015;10(4):321\u201346.","journal-title":"Curr Clin Pharmacol"},{"issue":"2","key":"3892_CR12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1161\/01.HYP.0000254479.66645.a3","volume":"49","author":"A Mahmud","year":"2007","unstructured":"Mahmud A, Feely J. Low-dose quadruple antihypertensive combination: more efficacious than individual agents\u2013a preliminary report. Hypertension. 2007;49(2):272\u20135.","journal-title":"Hypertension"},{"issue":"10073","key":"3892_CR13","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/S0140-6736(17)30260-X","volume":"389","author":"CK Chow","year":"2017","unstructured":"Chow CK, Thakkar J, Bennett A, Hillis G, Burke M, Usherwood T, et al. Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. Lancet. 2017;389(10073):1035\u201342.","journal-title":"Lancet"},{"issue":"6","key":"3892_CR14","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jama.2018.10359","volume":"320","author":"R Webster","year":"2018","unstructured":"Webster R, Salam A, de Silva HA, Selak V, Stepien S, Rajapakse S, et al. Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial. JAMA. 2018;320(6):566\u201379.","journal-title":"JAMA"},{"key":"3892_CR15","doi-asserted-by":"publisher","first-page":"5735","DOI":"10.2147\/DDDT.S286586","volume":"14","author":"SJ Hong","year":"2020","unstructured":"Hong SJ, Sung KC, Lim SW, Kim SY, Kim W, Shin J, et al. Low-Dose triple antihypertensive combination therapy in patients with hypertension: a randomized, double-blind, phase II study. Drug Des Devel Ther. 2020;14:5735\u201346.","journal-title":"Drug Des Devel Ther"},{"issue":"10305","key":"3892_CR16","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S0140-6736(21)01922-X","volume":"398","author":"CK Chow","year":"2021","unstructured":"Chow CK, Atkins ER, Hillis GS, Nelson MR, Reid CM, Schlaich MP, et al. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet. 2021;398(10305):1043\u201352.","journal-title":"Lancet"},{"key":"3892_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ahj.2023.05.019","volume":"264","author":"X Zhao","year":"2023","unstructured":"Zhao X, Chen Y, Yang G, Li X, Tang X, Yang Q, et al. Initial treatment with a single capsule containing half-dose quadruple therapy vs standard-dose dual therapy in hypertensive patients (QUADUAL): study protocol for a randomized, blinded, crossover trial. Am Heart J. 2023;264:10\u20139.","journal-title":"Am Heart J"},{"issue":"1","key":"3892_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13063-023-07803-1","volume":"25","author":"X Zhao","year":"2024","unstructured":"Zhao X, Li X, Liu T, Yang G, Chen Y, Huang M, et al. Initial treatment with a single capsule containing half-dose quadruple therapy versus standard-dose dual therapy in hypertensive patients (QUADUAL): statistical analysis plan for a randomized, blinded, crossover trial. Trials. 2024;25(1):45.","journal-title":"Trials"},{"issue":"2","key":"3892_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1161\/HYPERTENSIONAHA.122.20141","volume":"80","author":"LF Buckley","year":"2023","unstructured":"Buckley LF, Baker WL, Van Tassell BW, Cohen JB, Alkhezi O, Bress AP, et al. Systolic Blood Pressure Time in Target Range and Major Adverse Kidney and Cardiovascular Events. Hypertension. 2023;80(2):305\u201313.","journal-title":"Hypertension"},{"key":"3892_CR20","volume-title":"FDA bioequivalence standards","author":"X Lawrence","year":"2014","unstructured":"Lawrence X, Yu BVL. FDA Bioequivalence Standards. London: Springer, New York Heidelberg Dordrecht London; 2014."},{"key":"3892_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-81865-4","volume-title":"Analysis of data from randomized controlled trials: a practical guide","author":"JWR Twisk","year":"2021","unstructured":"Twisk JWR. Analysis of data from randomized controlled trials: a practical guide. Switzerland: Springer Nature Switzerland AG; 2021."},{"issue":"9426","key":"3892_CR22","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(04)16456-8","volume":"363","author":"MA Weber","year":"2004","unstructured":"Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363(9426):2049\u201351.","journal-title":"Lancet"},{"issue":"2","key":"3892_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1161\/HYPERTENSIONAHA.112.201566","volume":"61","author":"AH Gradman","year":"2013","unstructured":"Gradman AH, Parise H, Lefebvre P, Falvey H, Lafeuille MH, Duh MS. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension. 2013;61(2):309\u201318.","journal-title":"Hypertension"},{"issue":"4","key":"3892_CR24","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1161\/HYPERTENSIONAHA.111.177592","volume":"58","author":"G Corrao","year":"2011","unstructured":"Corrao G, Nicotra F, Parodi A, Zambon A, Heiman F, Merlino L, et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension. 2011;58(4):566\u201372.","journal-title":"Hypertension"},{"issue":"5","key":"3892_CR25","first-page":"881","volume":"7","author":"JM Yu","year":"2015","unstructured":"Yu JM, Kong QY, Shen T, He YS, Wang JW, Zhao YP. Benefit of initial dual-therapy on stroke prevention in Chinese hypertensive patients: a real world cohort study. J Thorac Dis. 2015;7(5):881\u20139.","journal-title":"J Thorac Dis"},{"issue":"8","key":"3892_CR26","doi-asserted-by":"publisher","first-page":"e1001860","DOI":"10.1371\/journal.pmed.1001860","volume":"12","author":"D Gu","year":"2015","unstructured":"Gu D, He J, Coxson PG, Rasmussen PW, Huang C, Thanataveerat A, et al. The cost-effectiveness of low-cost essential antihypertensive medicines for hypertension control in China: a modelling study. PLoS Med. 2015;12(8):e1001860.","journal-title":"PLoS Med"},{"issue":"9","key":"3892_CR27","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jama.2013.184182","volume":"310","author":"CK Chow","year":"2013","unstructured":"Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310(9):959\u201368.","journal-title":"JAMA"},{"issue":"1","key":"3892_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1161\/HYPERTENSIONAHA.120.15462","volume":"77","author":"J An","year":"2021","unstructured":"An J, Luong T, Qian L, Wei R, Liu R, Muntner P, et al. Treatment patterns and blood pressure control with initiation of combination versus monotherapy antihypertensive regimens. Hypertension. 2021;77(1):103\u201313.","journal-title":"Hypertension"},{"issue":"2","key":"3892_CR29","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/HJH.0000000000001181","volume":"35","author":"G Mancia","year":"2017","unstructured":"Mancia G, Rea F, Cuspidi C, Grassi G, Corrao G. Blood pressure control in hypertension. Pros and cons of available treatment strategies. J Hypertens. 2017;35(2):225\u201333.","journal-title":"J Hypertens."},{"issue":"2","key":"3892_CR30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/HJH.0000000000000409","volume":"33","author":"G Mancia","year":"2015","unstructured":"Mancia G, Asmar R, Amodeo C, Mourad JJ, Taddei S, Gamba MA, et al. Comparison of single-pill strategies first line in hypertension: perindopril\/amlodipine versus valsartan\/amlodipine. J Hypertens. 2015;33(2):401\u201311.","journal-title":"J Hypertens"},{"issue":"2","key":"3892_CR31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jash.2010.03.001","volume":"4","author":"AH Gradman","year":"2010","unstructured":"Gradman AH, Basile JN, Carter BL, Bakris GL, Materson BJ, Black HR, et al. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(2):90\u20138.","journal-title":"J Am Soc Hypertens"},{"issue":"7","key":"3892_CR32","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.amjhyper.2007.02.017","volume":"20","author":"MR Weir","year":"2007","unstructured":"Weir MR, Levy D, Crikelair N, Rocha R, Meng X, Glazer R. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens. 2007;20(7):807\u201315.","journal-title":"Am J Hypertens"},{"issue":"9762","key":"3892_CR33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S0140-6736(10)62003-X","volume":"377","author":"MJ Brown","year":"2011","unstructured":"Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet. 2011;377(9762):312\u201320.","journal-title":"Lancet"},{"issue":"12","key":"3892_CR34","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874\u20132071.","journal-title":"J Hypertens"},{"issue":"31","key":"3892_CR35","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1093\/eurheartj\/ehae337","volume":"45","author":"M B\u00f6hm","year":"2024","unstructured":"B\u00f6hm M, de la Sierra A, Mahfoud F, Schwantke I, Lauder L, Haring B, et al. Office measurement vs. ambulatory blood pressure monitoring: associations with mortality in patients with or without diabetes. Eur Heart J. 2024;45(31):2851\u201361.","journal-title":"Eur Heart J."},{"issue":"10393","key":"3892_CR36","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/S0140-6736(23)00733-X","volume":"401","author":"N Staplin","year":"2023","unstructured":"Staplin N, de la Sierra A, Ruilope LM, Emberson JR, Vinyoles E, Gorostidi M, et al. Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients. Lancet. 2023;401(10393):2041\u201350.","journal-title":"Lancet"},{"issue":"9","key":"3892_CR37","doi-asserted-by":"publisher","first-page":"e0202359","DOI":"10.1371\/journal.pone.0202359","volume":"13","author":"SC Chung","year":"2018","unstructured":"Chung SC, Pujades-Rodriguez M, Duyx B, Denaxas SC, Pasea L, Hingorani A, et al. Time spent at blood pressure target and the risk of death and cardiovascular diseases. PLoS One. 2018;13(9):e0202359.","journal-title":"PLoS One"},{"issue":"11","key":"3892_CR38","doi-asserted-by":"publisher","first-page":"e007131","DOI":"10.1161\/JAHA.117.007131","volume":"6","author":"M Doumas","year":"2017","unstructured":"Doumas M, Tsioufis C, Fletcher R, Amdur R, Faselis C, Papademetriou V. Time in therapeutic range, as a determinant of all-cause mortality in patients with hypertension. J Am Heart Assoc. 2017;6(11):e007131.","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"3892_CR39","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jacc.2021.01.014","volume":"77","author":"N Fatani","year":"2021","unstructured":"Fatani N, Dixon DL, Van Tassell BW, Fanikos J, Buckley LF. Systolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension. J Am Coll Cardiol. 2021;77(10):1290\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3892_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13293-020-00306-7","volume":"11","author":"AR Sabbatini","year":"2020","unstructured":"Sabbatini AR, Kararigas G. Estrogen-related mechanisms in sex differences of hypertension and target organ damage. Biol Sex Differ. 2020;11(1):31.","journal-title":"Biol Sex Differ"},{"issue":"9489","key":"3892_CR41","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"B Dahl\u00f6f","year":"2005","unstructured":"Dahl\u00f6f B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895\u2013906.","journal-title":"Lancet"},{"issue":"23","key":"3892_CR42","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, Dahl\u00f6f B, Pitt B, Shi V, et al. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. New Engl J Med. 2008;359(23):2417\u201328.","journal-title":"New Engl J Med"},{"issue":"9153","key":"3892_CR43","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","volume":"353","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353(9153):611\u20136.","journal-title":"Lancet"},{"issue":"3","key":"3892_CR44","doi-asserted-by":"publisher","first-page":"e223877","DOI":"10.1001\/jamanetworkopen.2022.3877","volume":"5","author":"Y Lu","year":"2022","unstructured":"Lu Y, Van Zandt M, Liu Y, Li J, Wang X, Chen Y, et al. Analysis of dual combination therapies used in treatment of hypertension in a multinational cohort. JAMA Netw Open. 2022;5(3):e223877.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"3892_CR45","first-page":"182","volume":"16","author":"Joint Committee for Guideline R","year":"2019","unstructured":"Joint Committee for Guideline R. 2018 Chinese guidelines for prevention and treatment of hypertension-a report of the revision committee of chinese guidelines for prevention and treatment of hypertension. J Geriatr Cardiol. 2019;16(3):182\u2013241.","journal-title":"J Geriatr Cardiol"},{"issue":"3","key":"3892_CR46","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/HJH.0b013e3283350ea4","volume":"28","author":"E Lambert","year":"2010","unstructured":"Lambert E, Dawood T, Straznicky N, Sari C, Schlaich M, Esler M, et al. Association between the sympathetic firing pattern and anxiety level in patients with the metabolic syndrome and elevated blood pressure. J Hypertens. 2010;28(3):543\u201350.","journal-title":"J Hypertens"},{"issue":"1\u20132","key":"3892_CR47","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jns.2012.02.014","volume":"317","author":"Z Bajk\u00f3","year":"2012","unstructured":"Bajk\u00f3 Z, Szekeres CC, Kov\u00e1cs KR, Csap\u00f3 K, Moln\u00e1r S, Solt\u00e9sz P, et al. Anxiety, depression and autonomic nervous system dysfunction in hypertension. J Neurol Sci. 2012;317(1\u20132):112\u20136.","journal-title":"J Neurol Sci"},{"key":"3892_CR48","first-page":"1121","volume":"11","author":"Y Pan","year":"2015","unstructured":"Pan Y, Cai W, Cheng Q, Dong W, An T, Yan J. Association between anxiety and hypertension: a systematic review and meta-analysis of epidemiological studies. Neuropsychiatr Dis Treat. 2015;11:1121\u201330.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"12","key":"3892_CR49","doi-asserted-by":"publisher","first-page":"e13426","DOI":"10.1111\/ijcp.13426","volume":"73","author":"J Liu","year":"2019","unstructured":"Liu J, Lu X, Chen L, Huo Y. Expert consensus on the management of hypertension in the young and middle-aged Chinese population. Int J Clin Pract. 2019;73(12):e13426.","journal-title":"Int J Clin Pract."},{"issue":"13","key":"3892_CR50","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJM200003303421301","volume":"342","author":"TW Gress","year":"2000","unstructured":"Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL, S ARC. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. New Engl J Med. 2000;342(13):905\u201312.","journal-title":"New Engl J Med"},{"issue":"6","key":"3892_CR51","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s11606-020-05731-3","volume":"35","author":"JJ Hall","year":"2020","unstructured":"Hall JJ, Eurich DT, Nagy D, Tjosvold L, Gamble JM. Thiazide diuretic-induced change in fasting plasma glucose: a meta-analysis of randomized clinical trials. J Gen Intern Med. 2020;35(6):1849\u201360.","journal-title":"J Gen Intern Med"},{"issue":"3","key":"3892_CR52","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41440-019-0356-x","volume":"43","author":"Y Ohta","year":"2020","unstructured":"Ohta Y, Kamide K, Hanada H, Morimoto S, Nakahashi T, Takiuchi S, et al. Genetic factors associated with elevation of uric acid after treatment with thiazide-like diuretic in patients with essential hypertension. Hypertens Res. 2020;43(3):220\u20136.","journal-title":"Hypertens Res"},{"key":"3892_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1475-2840-10-45","volume":"10","author":"Y Takahashi","year":"2011","unstructured":"Takahashi Y, Nishida Y, Nakayama T, Asai S. Adverse effect profile of trichlormethiazide: a retrospective observational study. Cardiovasc Diabetol. 2011;10:45.","journal-title":"Cardiovasc Diabetol"},{"issue":"18","key":"3892_CR54","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1001\/jama.2022.19590","volume":"328","author":"RM Carey","year":"2022","unstructured":"Carey RM, Moran AE, Whelton PK. Treatment of hypertension: a review. JAMA. 2022;328(18):1849\u201361.","journal-title":"JAMA"},{"issue":"5","key":"3892_CR55","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41371-022-00704-x","volume":"37","author":"Z Lin","year":"2023","unstructured":"Lin Z, Li HL, Tsoi MF, Cheung BMY. Hypokalaemia associated with hydrochlorothiazide used in the treatment of hypertension in NHANES 1999\u20132018. J Hum Hypertens. 2023;37(5):354\u201362.","journal-title":"J Hum Hypertens"},{"issue":"10","key":"3892_CR56","doi-asserted-by":"publisher","first-page":"E465","DOI":"10.1161\/STR.0000000000000443","volume":"54","author":"NR Gonzalez","year":"2023","unstructured":"Gonzalez NR, Amin-Hanjani S, Bang OY, Coffey C, Du RS, Fierstra J, et al. Adult moyamoya disease and syndrome: current perspectives and future directions: a scientific statement from the American Heart Association\/American Stroke Association. Stroke. 2023;54(10):E465\u201379.","journal-title":"Stroke"},{"issue":"2","key":"3892_CR57","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.120.15781","volume":"77","author":"G Parati","year":"2021","unstructured":"Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension. 2021;77(2):692\u2013705.","journal-title":"Hypertension"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-03892-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-03892-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-03892-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T14:35:58Z","timestamp":1738161358000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-03892-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3892"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-03892-8","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"21 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional Review Board of the Third Xiangya Hospital, Central South University approved this trial (approval number R22023 and R22152). The purpose and method of the study were informed in detail and the written informed consent was obtained before enrollment from all the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}